Abbvie Inc. Common Stock (ABBV) 50.91 $ABBV
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free.
2 Health Care Stocks to Watch: Enanta Pharmaceuticals, Inc. and PDLI BioPharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 02, 5:24PM CDT
Bargain hunters have largely stayed away from health-care stocks over the last year and for good reason. Specifically, this group of stocks has generally soared to record high price-to-earnings ratios ever since 2012, making them some of the most...
Medical Devices Face Onslaught Of Pricing Pressure
at Investor's Business Daily - Fri May 02, 4:26PM CDT
Makers of medical devices are coming under increasing pressure, owing to a fundamental power shift in American medicine favoring insurance companies, hospitals and their patients. The change, according to Moty Avisar, president of medical systems...
Approvals from the European Commission and Release of Quarterly Financial Results - Analyst Notes on Merck, Johnson & Johnson, Bristol-Myers Squibb, Teva and AbbVie
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1946-100free.
MedTech's Partial Tax Repeal: Is It Enough? - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:03AM CDT
MedTech's Partial Tax Repeal: Is It Enough? - Zacks Analyst Interviews
MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:03AM CDT
MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook
Active Equities Technical Coverage -- Research on Mondelez Intl., Time Warner, AbbVie, and FireEye
PR Newswire - Thu May 01, 3:40AM CDT
The U.S. stock markets on Tuesday, April 29, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,535.37, up 0.53% and the NASDAQ Composite closed at 4,103.54, up 0.72%. The S&P 500 finished the session 0.48% higher at 1,878.33. During the trading session, eight out of ten sectors finished on a higher note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Mondelez International Inc. (NASDAQ: MDLZ), Time Warner Inc. (NYSE: TWX), AbbVie Inc. (NYSE: ABBV) and FireEye Inc. (NASDAQ: FEYE). Free technical research on MDLZ, TWX, ABBV and FEYE can be downloaded upon signing up at:
Earnings Roundup: Is AbbVie on Borrowed Time?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
AbbVie 's better-than-hoped first-quarter earnings has shares rallying since mid-month. However, shares remain down on the year on concerns that its new hepatitis C drug won't live up to expectations and be able to blunt the eventual risk of patent...
Jim Cramer: Spend Is a Four-Letter Word
at The Street - Wed Apr 30, 10:26AM CDT
The market wants companies that are taking share with minimal spending.
Key Takeaways From Gilead Sciences' First Quarter
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Last week, Gilead Sciences revealed first quarter results that took analysts by surprise. Earnings per share of $1.33 came in almost 50% above the average estimate of $0.89. Total revenue of $5 billion was 27.6% above the average estimate of $3.92...
Will These 3 Drugs Keep AbbVie's Future Bright After Humira?
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
AbbVie has struggled to keep up with its industry peers this year. The stock's down double-digit percentages in 2014 despite strong sales growth from top drug Humira, the immunology therapy that made up around 58% of AbbVie's total revenue in its...
Stock Market News for April 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 9:06AM CDT
Benchmarks finished Monday’s choppy run mostly higher as investor sentiment following new deals in the health care sector, positive pending home sales data and intense selling pressure on internet stocks
Global Peritoneal Tumor Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7vbm9/peritoneal_tumor) has announced the addition of the "Peritoneal Tumor - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Tumor and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Tumor - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Tumor and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Latest news and deals relating related to pipeline products Companies Mentioned - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - Cell Therapeutics, Inc. - MEI Pharma, Inc. - Recepta Biopharma S.A. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/t7...neal_tumor
Global Refractory Chronic Lymphocytic Leukemia (CLL) Clinical Trials Report 2014 - Analysis of 19 Top Companies/Institutions
M2 - Tue Apr 29, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wnsqds/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014" provides data on the Refractory Chronic Lymphocytic Leukemia (CLL) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Chronic Lymphocytic Leukemia (CLL). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Chronic Lymphocytic Leukemia (CLL). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials - F. Hoffmann-La Roche Ltd. - Celgene Corporation - Pharmacyclics, Inc. - Janssen Global Services, LLC - GlaxoSmithKline plc - AbbVie Inc. - Gilead Sciences, Inc. - Sanofi - Merck & Co., Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Case Comprehensive Cancer Center - Roswell Park Cancer Institute - Ohio State University Comprehensive Cancer Center - Mayo Clinic - Beth Israel Deaconess Medical Center - Massachusetts General Hospital - Duke University For more information visit http://www.researchandmarkets.com/research/wnsqds/refractory
Global Refractory Acute Myeloid Leukemia Clinical Trials Review 2014
M2 - Tue Apr 29, 5:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpqqxj/refractory_acute) has announced the addition of the "Global Refractory Acute Myeloid Leukemia Clinical Trials Review 2014" report to their offering. Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Acute Myeloid Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Acute Myeloid Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Acute Myeloid Leukemia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - Novartis AG - Pfizer Inc. - Celgene Corporation - Sanofi - C. H. Boehringer Sohn AG & Co. KG - Ambit Biosciences Corporation - F. Hoffmann-La Roche Ltd. - AROG Pharmaceuticals LLC - Amgen Inc. - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Children's Oncology Group - The University of Texas M. D. Anderson Cancer Center - Stanford University - Washington University School of Medicine - Roswell Park Cancer Institute - Sidney Kimmel Comprehensive Cancer Center - Case Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/tp...tory_acute
What You Need to Know About New Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
According to Express Scripts 2013 Drug Spending Trends report, spending on hepatitis C drugs will soar 102% this year and more than 200% next year, as doctors increasingly prescribe next-generation treatments from Gilead and Johnson & Johnson...
Global Uveitis Therapeutics Pipeline Review 2014 - Analysis of 20 Companies & 30 Drug Profiles
M2 - Mon Apr 28, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6t3qv8/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Uveitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Alcon, Inc. - pSivida Corp. - Inovio Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - TheraKine Ltd. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - Regeneron Pharmaceuticals, Inc. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - Clearside BioMedical, Inc. - AbbVie Inc. - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - voclosporin - fluocinolone acetonide - gevokizumab - sarilumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - Optiquel - interferon gamma-1b - ustekinumab - triamcinolone acetonide - VGX-1027 - HL-036 - PA-2612 - EBI-006 - ATX-UV2 - P-13 - IBI-70090 - EC-1669 - TNP-470 - PP-001 - EBI-028 - Col-Treg - ATX-UV1 - Narrow Spectrum Kinase Inhibitors - OPK-20018 - INV-17 For more information visit http://www.researchandmarkets.com/research/6t3qv8/uveitis
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard
PR Newswire - Mon Apr 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Actavis Plc (NYSE: ACT) and C.R. Bard Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1687-100free.
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease
Global Metastatic Ovarian Cancer Clinical Trials Report 2014
M2 - Mon Apr 28, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4dxh6f/metastatic) has announced the addition of the "Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Ovarian Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Ovarian Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - F. Hoffmann-La Roche Ltd. - MolMed S.p.A. - Isis Pharmaceuticals, Inc. - E. Merck KG - Daiichi Sankyo Company, Limited - AbbVie Inc. - Eli Lilly and Company - Cell Therapeutics, Inc. - California Stem Cell, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - NCIC Clinical Trials Group - University of Washington - The University of Texas Health Science Center at San Antonio - Rutgers, The State University of New Jersey - European Organization for Research and Treatment of Cancer - Albert Einstein College of Medicine of Yeshiva University - Karolinska Institutet - Weill Cornell Medical College For more information visit http://www.researchandmarkets.com/research/4dxh6f/metastatic
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free.
2 Health Care Stocks to Watch: Enanta Pharmaceuticals, Inc. and PDLI BioPharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 02, 5:24PM CDT
Bargain hunters have largely stayed away from health-care stocks over the last year and for good reason. Specifically, this group of stocks has generally soared to record high price-to-earnings ratios ever since 2012, making them some of the most...
Medical Devices Face Onslaught Of Pricing Pressure
at Investor's Business Daily - Fri May 02, 4:26PM CDT
Makers of medical devices are coming under increasing pressure, owing to a fundamental power shift in American medicine favoring insurance companies, hospitals and their patients. The change, according to Moty Avisar, president of medical systems...
Approvals from the European Commission and Release of Quarterly Financial Results - Analyst Notes on Merck, Johnson & Johnson, Bristol-Myers Squibb, Teva and AbbVie
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1946-100free.
MedTech's Partial Tax Repeal: Is It Enough? - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:03AM CDT
MedTech's Partial Tax Repeal: Is It Enough? - Zacks Analyst Interviews
MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:03AM CDT
MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook
Active Equities Technical Coverage -- Research on Mondelez Intl., Time Warner, AbbVie, and FireEye
PR Newswire - Thu May 01, 3:40AM CDT
The U.S. stock markets on Tuesday, April 29, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,535.37, up 0.53% and the NASDAQ Composite closed at 4,103.54, up 0.72%. The S&P 500 finished the session 0.48% higher at 1,878.33. During the trading session, eight out of ten sectors finished on a higher note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Mondelez International Inc. (NASDAQ: MDLZ), Time Warner Inc. (NYSE: TWX), AbbVie Inc. (NYSE: ABBV) and FireEye Inc. (NASDAQ: FEYE). Free technical research on MDLZ, TWX, ABBV and FEYE can be downloaded upon signing up at:
Earnings Roundup: Is AbbVie on Borrowed Time?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
AbbVie 's better-than-hoped first-quarter earnings has shares rallying since mid-month. However, shares remain down on the year on concerns that its new hepatitis C drug won't live up to expectations and be able to blunt the eventual risk of patent...
Jim Cramer: Spend Is a Four-Letter Word
at The Street - Wed Apr 30, 10:26AM CDT
The market wants companies that are taking share with minimal spending.
Key Takeaways From Gilead Sciences' First Quarter
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Last week, Gilead Sciences revealed first quarter results that took analysts by surprise. Earnings per share of $1.33 came in almost 50% above the average estimate of $0.89. Total revenue of $5 billion was 27.6% above the average estimate of $3.92...
Will These 3 Drugs Keep AbbVie's Future Bright After Humira?
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
AbbVie has struggled to keep up with its industry peers this year. The stock's down double-digit percentages in 2014 despite strong sales growth from top drug Humira, the immunology therapy that made up around 58% of AbbVie's total revenue in its...
Stock Market News for April 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 9:06AM CDT
Benchmarks finished Monday’s choppy run mostly higher as investor sentiment following new deals in the health care sector, positive pending home sales data and intense selling pressure on internet stocks
Global Peritoneal Tumor Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7vbm9/peritoneal_tumor) has announced the addition of the "Peritoneal Tumor - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Tumor and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Tumor - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Tumor and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Latest news and deals relating related to pipeline products Companies Mentioned - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - Cell Therapeutics, Inc. - MEI Pharma, Inc. - Recepta Biopharma S.A. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/t7...neal_tumor
Global Refractory Chronic Lymphocytic Leukemia (CLL) Clinical Trials Report 2014 - Analysis of 19 Top Companies/Institutions
M2 - Tue Apr 29, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wnsqds/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014" provides data on the Refractory Chronic Lymphocytic Leukemia (CLL) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Chronic Lymphocytic Leukemia (CLL). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Chronic Lymphocytic Leukemia (CLL). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials - F. Hoffmann-La Roche Ltd. - Celgene Corporation - Pharmacyclics, Inc. - Janssen Global Services, LLC - GlaxoSmithKline plc - AbbVie Inc. - Gilead Sciences, Inc. - Sanofi - Merck & Co., Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Case Comprehensive Cancer Center - Roswell Park Cancer Institute - Ohio State University Comprehensive Cancer Center - Mayo Clinic - Beth Israel Deaconess Medical Center - Massachusetts General Hospital - Duke University For more information visit http://www.researchandmarkets.com/research/wnsqds/refractory
Global Refractory Acute Myeloid Leukemia Clinical Trials Review 2014
M2 - Tue Apr 29, 5:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpqqxj/refractory_acute) has announced the addition of the "Global Refractory Acute Myeloid Leukemia Clinical Trials Review 2014" report to their offering. Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Acute Myeloid Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Acute Myeloid Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Acute Myeloid Leukemia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - Novartis AG - Pfizer Inc. - Celgene Corporation - Sanofi - C. H. Boehringer Sohn AG & Co. KG - Ambit Biosciences Corporation - F. Hoffmann-La Roche Ltd. - AROG Pharmaceuticals LLC - Amgen Inc. - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Children's Oncology Group - The University of Texas M. D. Anderson Cancer Center - Stanford University - Washington University School of Medicine - Roswell Park Cancer Institute - Sidney Kimmel Comprehensive Cancer Center - Case Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/tp...tory_acute
What You Need to Know About New Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
According to Express Scripts 2013 Drug Spending Trends report, spending on hepatitis C drugs will soar 102% this year and more than 200% next year, as doctors increasingly prescribe next-generation treatments from Gilead and Johnson & Johnson...
Global Uveitis Therapeutics Pipeline Review 2014 - Analysis of 20 Companies & 30 Drug Profiles
M2 - Mon Apr 28, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6t3qv8/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Uveitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Alcon, Inc. - pSivida Corp. - Inovio Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - TheraKine Ltd. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - Regeneron Pharmaceuticals, Inc. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - Clearside BioMedical, Inc. - AbbVie Inc. - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - voclosporin - fluocinolone acetonide - gevokizumab - sarilumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - Optiquel - interferon gamma-1b - ustekinumab - triamcinolone acetonide - VGX-1027 - HL-036 - PA-2612 - EBI-006 - ATX-UV2 - P-13 - IBI-70090 - EC-1669 - TNP-470 - PP-001 - EBI-028 - Col-Treg - ATX-UV1 - Narrow Spectrum Kinase Inhibitors - OPK-20018 - INV-17 For more information visit http://www.researchandmarkets.com/research/6t3qv8/uveitis
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard
PR Newswire - Mon Apr 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Actavis Plc (NYSE: ACT) and C.R. Bard Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1687-100free.
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease
Global Metastatic Ovarian Cancer Clinical Trials Report 2014
M2 - Mon Apr 28, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4dxh6f/metastatic) has announced the addition of the "Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Ovarian Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Ovarian Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - F. Hoffmann-La Roche Ltd. - MolMed S.p.A. - Isis Pharmaceuticals, Inc. - E. Merck KG - Daiichi Sankyo Company, Limited - AbbVie Inc. - Eli Lilly and Company - Cell Therapeutics, Inc. - California Stem Cell, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - NCIC Clinical Trials Group - University of Washington - The University of Texas Health Science Center at San Antonio - Rutgers, The State University of New Jersey - European Organization for Research and Treatment of Cancer - Albert Einstein College of Medicine of Yeshiva University - Karolinska Institutet - Weill Cornell Medical College For more information visit http://www.researchandmarkets.com/research/4dxh6f/metastatic
